The European Bank for Reconstruction and Development (EBRD) has increased its equity stake in Famar, committing an additional €5.2m as part of a capital increase led by MidEuropa and co-investors.

The fresh capital will fund Famar’s acquisition of a sterile manufacturing site in Homburg, Germany, while EBRD’s contribution will specifically finance capital expenditure in Greece. Investments will include new production lines, labelling machines, and upgrades to existing facilities.

This follows EBRD’s €24m equity investment last year, which supported MidEuropa’s acquisition of Famar. The company has since outperformed expectations, particularly in sterile products, prompting further expansion to strengthen its product mix in higher value-added pharmaceuticals.

Famar manufactures and distributes pharmaceutical, consumer health, and cosmetic products for an international blue-chip client base. Alongside operations in Greece, the group also has facilities in Italy, Spain, and now Germany.

Since beginning operations in Greece in 2015, EBRD has invested more than €8.5bn across 118 projects to support the country’s economic recovery.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com.

Can`t stop reading? Read more.